The change in price came along side change in volume that was up 8.44% from previous day, but down 24.09% from the wednesday of last week.
V=tqcdykgoi2g $aytu not only is josh disbrow the ceo for aytu he also sits on the board of this company $zyxi and also three weeks ago watch this video this chart is still bullish and also if you understand they are approaching the virus a whole new approach and big pharma hates it because they want the average joe to pop pills and get injected with unnecessary vaccine. especially the ones who hate and protests against big pharma pills and vaccines.
The price move occurred on volume that was up 3.1% from the day prior, but down 26.59% from the same day the week before.
It will also reserve a portion of its manufacturing capabilities to continue making the vaccine in 2021.
This is the first in a series of prospective global collab agreements designed to accelerate manufacturing of j&j's covid-19 vaccine candidate, and further the company's goal to supply more than 1b doses of the vaccine globally.
As for how volume fared, yesterday’s volume was up 14.65% from the previous day (tuesday), and up 42.3% from wednesday of the week before.
While i can rationalize a value of jnj around $135-$140 based on current 2020 guidance & dividend increases, it has no business being anywhere in the 150s.
This move happened on lower volume, as yesterday’s volume was down 10.34% from the day before — and down 4.07% from the same day the week before.